FY2024 Earnings Estimate for VKTX Issued By Leerink Partnrs

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Stock analysts at Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for Viking Therapeutics in a research report issued to clients and investors on Thursday, October 24th. Leerink Partnrs analyst T. Smith now forecasts that the biotechnology company will earn ($0.92) per share for the year, up from their prior forecast of ($0.94). The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.00) per share. Leerink Partnrs also issued estimates for Viking Therapeutics’ Q4 2024 earnings at ($0.24) EPS, FY2025 earnings at ($1.65) EPS, FY2026 earnings at ($2.41) EPS, FY2027 earnings at ($3.83) EPS and FY2028 earnings at ($1.31) EPS.

Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings data on Wednesday, October 23rd. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.02. During the same quarter in the previous year, the company earned ($0.23) EPS.

VKTX has been the topic of several other reports. Oppenheimer reaffirmed an “outperform” rating and set a $138.00 price objective on shares of Viking Therapeutics in a research report on Wednesday, September 25th. Raymond James lifted their price target on Viking Therapeutics from $116.00 to $118.00 and gave the company a “strong-buy” rating in a research report on Thursday, July 25th. Morgan Stanley reiterated an “overweight” rating and issued a $105.00 price objective on shares of Viking Therapeutics in a report on Thursday, September 12th. StockNews.com upgraded shares of Viking Therapeutics to a “sell” rating in a report on Tuesday, October 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $90.00 target price on shares of Viking Therapeutics in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Viking Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $108.60.

Viking Therapeutics Trading Up 6.6 %

Shares of VKTX opened at $78.03 on Monday. Viking Therapeutics has a 1-year low of $8.28 and a 1-year high of $99.41. The firm has a market capitalization of $8.60 billion, a price-to-earnings ratio of -83.90 and a beta of 1.00. The firm’s 50-day moving average price is $63.67 and its 200-day moving average price is $61.61.

Institutional Trading of Viking Therapeutics

A number of large investors have recently made changes to their positions in VKTX. Blue Trust Inc. bought a new position in Viking Therapeutics during the third quarter valued at approximately $26,000. GAMMA Investing LLC raised its stake in Viking Therapeutics by 124.6% during the 3rd quarter. GAMMA Investing LLC now owns 438 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 243 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in Viking Therapeutics during the 2nd quarter valued at $27,000. Gilliland Jeter Wealth Management LLC bought a new position in shares of Viking Therapeutics during the 3rd quarter valued at $32,000. Finally, Massmutual Trust Co. FSB ADV boosted its stake in shares of Viking Therapeutics by 84.3% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 553 shares of the biotechnology company’s stock worth $35,000 after buying an additional 253 shares during the last quarter. 76.03% of the stock is currently owned by institutional investors.

Insider Activity at Viking Therapeutics

In other news, CEO Brian Lian sold 1,000 shares of the stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $69.90, for a total transaction of $69,900.00. Following the sale, the chief executive officer now owns 2,354,927 shares in the company, valued at $164,609,397.30. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, COO Marianna Mancini sold 18,026 shares of Viking Therapeutics stock in a transaction dated Tuesday, July 30th. The stock was sold at an average price of $57.13, for a total value of $1,029,825.38. Following the completion of the sale, the chief operating officer now directly owns 362,149 shares in the company, valued at approximately $20,689,572.37. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Brian Lian sold 1,000 shares of the business’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $69.90, for a total value of $69,900.00. Following the completion of the transaction, the chief executive officer now directly owns 2,354,927 shares of the company’s stock, valued at approximately $164,609,397.30. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 527,671 shares of company stock valued at $34,700,603. 4.70% of the stock is owned by insiders.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.